Literature DB >> 28402980

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.

Rodney J Hicks1, Dik J Kwekkeboom, Eric Krenning, Lisa Bodei, Simona Grozinsky-Glasberg, Rudolf Arnold, Ivan Borbath, Jaroslaw Cwikla, Christos Toumpanakis, Greg Kaltsas, Philippa Davies, Dieter Hörsch, Eva Tiensuu Janson, John Ramage.   

Abstract

Entities:  

Year:  2017        PMID： 28402980     DOI： 10.1159/000475526

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN： 0028-3835            Impact factor:   4.914


× No keyword cloud information.
  72 in total

Review 1.  Somatostatin receptor PET ligands - the next generation for clinical practice.

Authors:  Elin Pauwels; Frederik Cleeren; Guy Bormans; Christophe M Deroose
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

2.  177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study.

Authors:  Giovanni Paganelli; Maddalena Sansovini; Silvia Nicolini; Ilaria Grassi; Toni Ibrahim; Elena Amadori; Valentina Di Iorio; Manuela Monti; Emanuela Scarpi; Alberto Bongiovanni; Mattia Altini; Luca Urso; Corrado Cittanti; Federica Matteucci; Stefano Severi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-29       Impact factor: 9.236

Review 3.  Management of functional neuroendocrine tumors of the pancreas.

Authors:  Kjell Öberg
Journal:  Gland Surg       Date:  2018-02

Review 4.  Peptide Receptor Radiotherapy: Current Approaches and Future Directions.

Authors:  Grace Kong; Rodney J Hicks
Journal:  Curr Treat Options Oncol       Date:  2019-08-29

5.  High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.

Authors:  Rudolf A Werner; Thorsten Derlin; Steven P Rowe; Lena Bundschuh; Gabriel T Sheikh; Martin G Pomper; Sebastian Schulz; Takahiro Higuchi; Andreas K Buck; Frank M Bengel; Ralph A Bundschuh; Constantin Lapa
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 10.057

6.  Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.

Authors:  Stephan Petersenn; Christian A Koch
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

7.  64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy.

Authors:  Rodney J Hicks; Price Jackson; Grace Kong; Robert E Ware; Michael S Hofman; David A Pattison; Timothy A Akhurst; Elizabeth Drummond; Peter Roselt; Jason Callahan; Roger Price; Charmaine M Jeffery; Emily Hong; Wayne Noonan; Alan Herschtal; Lauren J Hicks; Amos Hedt; Matthew Harris; Brett M Paterson; Paul S Donnelly
Journal:  J Nucl Med       Date:  2018-11-15       Impact factor: 10.057

Review 8.  Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.

Authors:  Xi-Feng Jin; Matilde P Spampatti; Christine Spitzweg; Christoph J Auernhammer
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 9.  The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines.

Authors:  Wouter T Zandee; Wouter W de Herder
Journal:  Neuroendocrinology       Date:  2018-01-10       Impact factor: 4.914

10.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.